Acorda Therapeutics (ACOR) : Investors lapped up stocks on upticks to the tune of $10.1 million in the Wednesdays trading session. The trading value on downticks was comparatively at $5.06 million and the uptick to downtick ratio of 1.99 indicates continuous buying by the bulls. The net money flow into the stock was $5.03 million. Upticks saw transactions worth $5.25 clearly indicating buying by large investors. The total money flow for block trades stood at $5.25 million, which is a positive for the stock in the long-term. Acorda Therapeutics (ACOR) fell $0.07 during the day at $21.99, a drop of -0.32% over the previous days close. However, for the week, the stock is -19.39%, compared to the previous week.
Acorda Therapeutics, Inc. has lost 18.77% in the last five trading days and dropped 10.35% in the last 4 weeks. Acorda Therapeutics, Inc. has dropped 13.39% during the last 3-month period . Year-to-Date the stock performance stands at -48.6%.
Acorda Therapeutics (ACOR) : 4 analysts are covering Acorda Therapeutics (ACOR) and their average rating on the stock is 1.5, which is read as a Strong Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Acorda Therapeutics (NASDAQ:ACOR): stock was range-bound between the intraday low of $21.7 and the intraday high of $22.3569 after having opened at $22.25 on Wednesdays session. The stock finally closed in the red at $22.25, a loss of -0.32%. The stock remained in the red for the whole trading day. The total traded volume was 1,560,223 shares. The stock failed to cross $22.3569 in Wednesdays trading. The stocks closing price on Thursday was $22.06.
Acorda Therapeutics, Inc. is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Companys markets three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10milligrams, a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders, including chronic post-stroke walking deficits (PSWD), Parkinsons disease, epilepsy, heart failure, MS, and spinal cord injury.